PD 169316 50mg 50mg | Purity Not Available
Adooq Bioscience
PD 169316 (PD169316) is a selective inhibitor of p38 MAPK.1 that inhibits p38 MAPK with an IC50 of 89 nM.
More Information Supplier PagePD 169316 (PD169316) is a selective inhibitor of p38 MAPK.1 that inhibits p38 MAPK with an IC50 of 89 nM.
More Information Supplier PagePD 169316 (PD169316) is a selective inhibitor of p38 MAPK.1 that inhibits p38 MAPK with an IC50 of 89 nM.
More Information Supplier PagePD 169316 (PD169316) is a selective inhibitor of p38 MAPK.1 that inhibits p38 MAPK with an IC50 of 89 nM.
More Information Supplier PagePD 169316 (PD169316) is a selective inhibitor of p38 MAPK.1 that inhibits p38 MAPK with an IC50 of 89 nM.
More Information Supplier PageJTT-705 (Dalcetrapib) is a CETP inhibitor.Inhibition of CETP is a target to increase HDL-cholesterol and potentially reduce atherosclerosis.
More Information Supplier PageJTT-705 (Dalcetrapib) is a CETP inhibitor.Inhibition of CETP is a target to increase HDL-cholesterol and potentially reduce atherosclerosis.
More Information Supplier PageJTT-705 (Dalcetrapib) is a CETP inhibitor.Inhibition of CETP is a target to increase HDL-cholesterol and potentially reduce atherosclerosis.
More Information Supplier PageJTT-705 (Dalcetrapib) is a CETP inhibitor.Inhibition of CETP is a target to increase HDL-cholesterol and potentially reduce atherosclerosis.
More Information Supplier PageJTT-705 (Dalcetrapib) is a CETP inhibitor.Inhibition of CETP is a target to increase HDL-cholesterol and potentially reduce atherosclerosis.
More Information Supplier PageBRL 52537 hydrochloride is a highly selective and potent ??-opioid agonist (Ki = 0.24 nM). 25 times more potent than morphine.
More Information Supplier Page